Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Operations: 2014-2024

Historic Cash from Operations for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $184.2 million.

  • Protagonist Therapeutics' Cash from Operations rose 93.05% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.5 million, marking a year-over-year decrease of 71.57%. This contributed to the annual value of $184.2 million for FY2024, which is 362.19% up from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' Cash from Operations is $184.2 million, which was up 362.19% from -$70.2 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Cash from Operations ranged from a high of $184.2 million in FY2024 and a low of -$108.1 million during FY2022.
  • Over the past 3 years, Protagonist Therapeutics' median Cash from Operations value was -$70.2 million (recorded in 2023), while the average stood at $1.9 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Cash from Operations plummeted by 74.55% in 2020 and then soared by 362.19% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Cash from Operations (Yearly) stood at -$72.5 million in 2020, then plummeted by 48.81% to -$107.9 million in 2021, then decreased by 0.25% to -$108.1 million in 2022, then skyrocketed by 35.05% to -$70.2 million in 2023, then skyrocketed by 362.19% to $184.2 million in 2024.